131 related articles for article (PubMed ID: 15128047)
21. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
22. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
[TBL] [Abstract][Full Text] [Related]
23. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
24. Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy.
Luxembourg B; Schneider K; Sittinger K; Toennes SW; Seifried E; Lindhoff-Last E; Oldenburg J; Geisen C
Thromb Haemost; 2011 Jan; 105(1):169-80. PubMed ID: 21057703
[TBL] [Abstract][Full Text] [Related]
25. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
26. Determination of bleeding risk using genetic markers in patients taking phenprocoumon.
Hummers-Pradier E; Hess S; Adham IM; Papke T; Pieske B; Kochen MM
Eur J Clin Pharmacol; 2003 Jul; 59(3):213-9. PubMed ID: 12728288
[TBL] [Abstract][Full Text] [Related]
27. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.
Henne KR; Gaedigk A; Gupta G; Leeder JS; Rettie AE
J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):143-8. PubMed ID: 9686881
[TBL] [Abstract][Full Text] [Related]
28. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.
Ochoa D; Prieto-Pérez R; Román M; Talegón M; Rivas A; Galicia I; Abad-Santos F; Cabaleiro T
Pharmacogenomics; 2015; 16(9):939-48. PubMed ID: 26122864
[TBL] [Abstract][Full Text] [Related]
29. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.
Dorado P; Berecz R; Norberto MJ; Yasar U; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 Jul; 59(3):221-5. PubMed ID: 12734606
[TBL] [Abstract][Full Text] [Related]
30. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
[TBL] [Abstract][Full Text] [Related]
31. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
32. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
34. Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
Steward DJ; Haining RL; Henne KR; Davis G; Rushmore TH; Trager WF; Rettie AE
Pharmacogenetics; 1997 Oct; 7(5):361-7. PubMed ID: 9352571
[TBL] [Abstract][Full Text] [Related]
35. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
López-Rodríguez R; Novalbos J; Gallego-Sandín S; Román-Martínez M; Torrado J; Gisbert JP; Abad-Santos F
Pharmacol Res; 2008 Jul; 58(1):77-84. PubMed ID: 18694831
[TBL] [Abstract][Full Text] [Related]
36. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.
Vianna-Jorge R; Perini JA; Rondinelli E; Suarez-Kurtz G
Clin Pharmacol Ther; 2004 Jul; 76(1):18-26. PubMed ID: 15229460
[TBL] [Abstract][Full Text] [Related]
37. Genetic variation at the CYP2C locus and its association with torsemide biotransformation.
Vormfelde SV; Schirmer M; Toliat MR; Meineke I; Kirchheiner J; Nürnberg P; Brockmöller J
Pharmacogenomics J; 2007 Jun; 7(3):200-11. PubMed ID: 16969365
[TBL] [Abstract][Full Text] [Related]
38. Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction.
Ufer M; Kammerer B; Kirchheiner J; Rane A; Svensson JO
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Oct; 809(2):217-26. PubMed ID: 15315768
[TBL] [Abstract][Full Text] [Related]
39. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
40. Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.
Kusama M; Maeda K; Chiba K; Aoyama A; Sugiyama Y
Pharm Res; 2009 Apr; 26(4):822-35. PubMed ID: 19082874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]